Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soon-Hin How

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Cancer Management and Research|March 20, 2026
Advancing Precision Medicine in Non-Small Cell Lung Cancer Diagnostics in a Southeast Asian CountryMau Ern Poh, Muthukkumaran Thiagarajan, Lye Mun Tho, et al.
Tropical Medicine and Infectious Disease|October 3, 2018
Melioidosis in Malaysia: Incidence, Clinical Challenges, and Advances in Understanding PathogenesisSheila Nathan, Sylvia Chieng, Paul Vijay Kingsley, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 18, 2014
Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic malaysian patient populationChong-Kin Liam, Hwong-Ruey Leow, Soon-Hin How, et al.
Translational Lung Cancer Research|August 9, 2024
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancerMau Ern Poh, Sivasubramaniam Balakrishnan, Sin Nee Tan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2019
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological SocietyPathmanathan Rajadurai, Phaik Leng Cheah, Soon Hin How, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2026
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1Jarushka Naidoo, Solange Peters, Yotsawaj Runglodvatana, et al.
Thoracic Cancer|May 3, 2022
Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited countrySoon Hin How, Lye Mun Tho, Chong Kin Liam, et al.
Translational Lung Cancer Research|March 18, 2024
Does dose reduction of afatinib affect treatment outcomes of patients with <i>EGFR</i>-mutant metastatic non-small cell lung cancer in real-world clinical practice?Mau Ern Poh, Chee Shee Chai, Chong Kin Liam, et al.
BMC Cancer|September 11, 2019
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational studyGwo-Fuang Ho, Chee-Shee Chai, Adlinda Alip, et al.
Cancer Management and Research|January 20, 2023
Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian CountryMau Ern Poh, Soon Hin How, Gwo Fuang Ho, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Cancer Management and Research|March 20, 2026
Advancing Precision Medicine in Non-Small Cell Lung Cancer Diagnostics in a Southeast Asian CountryMau Ern Poh, Muthukkumaran Thiagarajan, Lye Mun Tho, et al.
Tropical Medicine and Infectious Disease|October 3, 2018
Melioidosis in Malaysia: Incidence, Clinical Challenges, and Advances in Understanding PathogenesisSheila Nathan, Sylvia Chieng, Paul Vijay Kingsley, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 18, 2014
Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic malaysian patient populationChong-Kin Liam, Hwong-Ruey Leow, Soon-Hin How, et al.
Translational Lung Cancer Research|August 9, 2024
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancerMau Ern Poh, Sivasubramaniam Balakrishnan, Sin Nee Tan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2019
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological SocietyPathmanathan Rajadurai, Phaik Leng Cheah, Soon Hin How, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2026
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1Jarushka Naidoo, Solange Peters, Yotsawaj Runglodvatana, et al.
Thoracic Cancer|May 3, 2022
Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited countrySoon Hin How, Lye Mun Tho, Chong Kin Liam, et al.
Translational Lung Cancer Research|March 18, 2024
Does dose reduction of afatinib affect treatment outcomes of patients with <i>EGFR</i>-mutant metastatic non-small cell lung cancer in real-world clinical practice?Mau Ern Poh, Chee Shee Chai, Chong Kin Liam, et al.
BMC Cancer|September 11, 2019
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational studyGwo-Fuang Ho, Chee-Shee Chai, Adlinda Alip, et al.
Cancer Management and Research|January 20, 2023
Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian CountryMau Ern Poh, Soon Hin How, Gwo Fuang Ho, et al.
Pageof 3